| Summary: | Hepatocellular carcinoma (HCC) is the sixth most common type of cancer, with an increasing mortality rate. Aberrant expression of fibroblast growth factor 19−fibroblast growth factor receptor 4 (<i>FGF19−FGFR4</i>) is reported to be an oncogenic-driver pathway for HCC patients. Thus, the <i>FGF19−FGFR4</i> signaling pathway is a promising target for the treatment of HCC. Several pan-<i>FGFR</i> (1−4) and <i>FGFR4</i>-specific inhibitors are in different phases of clinical trials. In this review, we summarize the information, recent developments, binding modes, selectivity, and clinical trial phases of different available <i>FGFR4</i>/pan-<i>FGF</i> inhibitors. We also discuss future perspectives and highlight the points that should be addressed to improve the efficacy of these inhibitors.
|
|---|